Potentiation of Antiproliferative Drug Activity by Lonidamine in Hepatocellular Carcinoma Cells

REFERENCES

• Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357–361.
   PubMed Web of Science ®Google Scholar
• Ngan H. Lipiodol computerized tomography: how sensi-tive and specific is the technique in the diagnosis of hepatocel-lular carcinoma? Br J Radiol 1990; 63: 771–775.
   PubMed Web of Science ®Google Scholar
• Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepa-tectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547–1552.
   PubMed Web of Science ®Google Scholar
• Zhou XD, Tang ZY, Yu YQ et al. Long-term survivors after resection for primary liver cancer. Cancer 1989; 63: 2201–2206.
   Google Scholar
• CasteIls A, Bruix J, Ayuso C et al. Treatment of hepa-tocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917–922.
   Google Scholar
• Venook AP, Stagg RJ, Lewis BJ et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8: 1108–1114.
   PubMed Web of Science ®Google Scholar
• Groupe D'Etude et de Traitement du Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular car-cinoma. N Engl J Med 1995; 332: 1256–1261.
   Google Scholar
• Park JG, Lee SK, Hong IC et al. MDR1 gene expres-sion: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994; 86: 700–705.
   Google Scholar
• Johnson PJ, Dobbs N, Kalayci C et al. Clinical efficacy and toxicity of standard dose Adriamycin in hyperbilirubi-naemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65: 751–755.
   Google Scholar
• Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monother-apy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000; 12: 281–284.
   PubMed Web of Science ®Google Scholar
• Van Eeden H, Falkson G, Burger W, Ansell SM. 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Ann Oncol 1992; 3: 404–405.
   PubMed Web of Science ®Google Scholar
• Patt YZ, Charnsangaveg C, Yoffe B et al. Hepatic arte-rial infusion of floxuridine, leucovorin, doxorubicin and cis-platin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994; 12: 1204-1211.
   Google Scholar
• Bobbio-Pallavicini E, Porta C, Moroni M et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients. Eur J Cancer 1997; 33: 1784–1788.
   Google Scholar
• Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92: 1042–1053.
   PubMed Web of Science ®Google Scholar
• Dogliotti L, Berruti A, Buniva T et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 1996; 14: 1165-1172.
   Google Scholar
• Nistico C, Garufi C, Milella M et al. Weekly epirubicin plus lonidamine in advanced breast carcinoma. Breast Cancer Res Treat 1999; 56: 233–237.
   PubMed Web of Science ®Google Scholar
• Savini S, Zoli W, Nanni 0 et al. In vitro potentation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 1992; 24: 27–34.
   PubMed Web of Science ®Google Scholar
• Amadori D, Frassineti GL, De Matteis A et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 1998; 49: 209–217.
   Google Scholar
• Orlandi L, Zaffaroni N, Gornati D, Veneroni S, Silvestrini R. Potentation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. Anticancer Res 1994; 14: 1161–1164.
   PubMed Web of Science ®Google Scholar
• Orlandi L, Zaffaroni N, Bearzatto, Villa R, De Marco C, Silvestrini R. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. Int J Cancer 1998; 78: 377–384.
   PubMed Web of Science ®Google Scholar
• De Lena M, Lorusso V, Bottalico C et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol 1997; 15: 3208–3213.
   Google Scholar
• Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615–616.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D et al. New colorimet-ric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst 1990; 13: 1107–1112.
   Google Scholar
• Horikoshi N, Inoue K, Aiba K, T et al. Phase I study of paclitaxel. Jpn J Cancer Chemother 1994; 21: 2407–2414.
   PubMedGoogle Scholar
• Lankelma J, Stuurman M, van Hoogenhuijze J et al. The pharmacokinetic plasma profile of mitomycin C, mea-sured after sequential intermittent intravenous administration. Eur J Clin Oncol 1988; 24: 175–180.
   Google Scholar
• Camaggi CM, Strocchi E, Tamassia V et al. Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 1982; 66: 1819–1824.
   Google Scholar
• Findlay MP, Raynaud F, Cuningham D, Iveson A, Collins DJ, Leach MO. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F mag-netic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha. Ann Oncol 1996; 7: 47–53.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoi-somerase I and II in non-small cell lung cancer (NSCLC) sub-lines resistant to cisplatin. Anticancer Res 1995; 15: 393–398.
   PubMed Web of Science ®Google Scholar
• Newell DR, Mansi J, Hardy J et al. The pharmacoki-netics of oral lonidamine in breast and lung cancer patients. Semin Oncol 1991; 18: 11–17.
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cul-tured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757–766.
   Google Scholar
• Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumour activity with cis-diamminedichloroplatinum(II). Cancer Res 1988; 48: 117–121.
   PubMed Web of Science ®Google Scholar
• Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma sys-tems. Cancer Chemother Pharmacol 1998; 41: 385–390.
   PubMed Web of Science ®Google Scholar
• Flickinger JC, Carr BI, Lotze MT. Cancer of the liver. In: Devita VT, ed. Cancer: principles and practice of oncology. 5th ed. New York: Lippincot Company. 1997: 1087-1128.
   Google Scholar
• Strumberg D, Erhard J, Harstrick A et al. Phase I of a weekly lh infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 1998; 34: 1290–1292.
   Google Scholar
• Lui WY, Chang YF, Li LL et al. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. Anticancer Res 1998; 18: 3339–3345.
   Google Scholar
• Gagandeep S, Novikoff PM, Ott M, Gupta S. Paclitaxel shows cytotoxicity activity in human hepatocellular carcinoma cell lines. Cancer Lett 1999; 136: 109–118.
   PubMed Web of Science ®Google Scholar
• Ussat S, Werner UE, Kruse ML et al. Upregulation of p21 (WAF1/Cipl) precedes tumor necrosis factor-induced necrosis-like cell death. Biochem Biophys Res Commun 2002; 294: 672–679.
   Google Scholar
• Chen X, Zhang W, Gao YF, Su XQ, Zhai ZH. Senescence-like changes induced by expression of p21 (wafl/Cipl) in NIH3T3 cell line. Cell Res 2002; 12: 229–233.
   PubMed Web of Science ®Google Scholar
• Floridi A, Paggi MG, D'Atri S et al. Effect of lonidamine on the energy metabolism of Ehrlich ascite tumor cells. Cancer Res 1981; 41: 4661–4666.
   Google Scholar
• Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. Lonidamine, a selective inhibitor of murine cancer cells. J Natl Cancer Inst 1981; 66: 497–499.
   PubMed Web of Science ®Google Scholar